Amid the rapid surge of omicron cases across the nation, the Serum Institute Of India has submitted an application to the Central Drugs Standard Control Organization and the health ministry for full market authorisation of its COVID-19 vaccine, Covishield, the company’s chief executive said in a tweet on Friday.
Supplies of the COVISHIELD vaccine in India, have exceeded 1.25 billion doses. The government of India now has enough data for full market authorisation, and therefore @SerumInstIndia has applied to the @CDSCO_INDIA_INF (DCGI) and @MoHFW_INDIA for this permission.
— Adar Poonawalla (@adarpoonawalla) December 31, 2021
“Supplies of the COVISHIELD vaccine in India, have exceeded 1.25 billion doses. The government of India now has enough data for full market authorisation, and therefore serum institute of India has applied to the Central Drugs Standard Control Organisation(CDSCO) and Ministry of Health and Family Welfare, Government of India for this permission”, Adar Poonawala tweeted on Friday, December 31.
Earlier this week on Dec 28, the health ministry of India granted the permit for emergency use authorization for COVOVAX in India will is expected to be highly effective against COVID-19.
This is yet another milestone in our fight against COVID-19, Covovax is now W.H.O. approved for emergency use, showing excellent safety and efficacy. Thank you all for a great collaboration, @Novavax @WHO @GaviSeth @Gavi @gatesfoundation https://t.co/7C8RVZa3Y4
— Adar Poonawalla (@adarpoonawalla) December 17, 2021
Serum Institute has engineered AstraZeneca’s COVID-19 vaccine under the brand name Covishield which proved to be very effective in fighting the virus. India saw a 27% rise in the cases Of COVID -19 just in a day.
The Medicity in India found the COVISHIELD (ChAdOx1 nCoV-19 Corona Virus Vaccine) vaccine produced an immune response from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) two weeks after vaccination with limited side effects.
